In the LMP tumours, there were significantly more KRAS mutation-positive cases that were associated with a gain of 12p (8 of 12, 66.7%) than there were in KRAS mutation-negative tumours (4 of 41, 9.8%) (p = 0. The gene discussed is KRAS; the disease is neoplasm.